emerald-1 trial in hcc
Published 3 years ago • 320 plays • Length 3:38Download video MP4
Download video MP3
Similar videos
-
2:09
safey findings of emerald-1: durvalumab, bevacizumab and tace in hcc
-
0:51
emerald-1 trial: improved pfs w/ durvalumab bevacizumab tace vs tace in hepatocellular carcinoma
-
0:55
exploring durvalumab bevacizumab tace in hepatocellular carcinoma: emerald-1 insights
-
1:03
phase iii emerald-1: bevacizumab and durvalumab with tace improves pfs in unresectable hcc
-
1:34
emerald-1: durvalumab, bevacizumab and tace in unresectable hcc
-
2:33
emerald-3: tremelimumab durvalumab with or without lenvatinib combined with tace in hcc
-
4:56
himalaya: tremelimumab durvalumab in unresectable hcc
-
2:21
updated results by duration of prior cdk4/6i in the met setting of the phase iii emerald trial
-
7:47
combination tremelimumab and durvalumab in hcc
-
1:15
montblanc: sequential or up-front durvalumab, tremelimumab, bevacizumab in unresectable hcc
-
1:27
emerald: elacestrant vs physicians choice in er /her2- breast cancer
-
3:34
himalaya: does underlying liver function impact efficacy of tremelimumab plus durvalumab for hcc?
-
1:03
integrating immunotherapy and targeted therapy with tace in uhcc treatment
-
3:07
hcc and cca trials at esmo 2023: advantig-206 and abc-01
-
2:32
the role of systemic treatment in early-stage hepatocellular carcinoma
-
1:02
safety and management of combining immunotherapy and targeted therapy with tace in uhcc
-
1:00
prime-hcc: ipilimumab and nivolumab in liver cancer